Assessing QSAR Limitations - A Regulatory Perspective

Publisher： Bentham Science Publishers

E-ISSN： 1875-6697|1|2|195-205

ISSN： 1573-4099

Source： Current Computer - Aided Drug Design, Vol.1, Iss.2, 2005-04, pp. : 195-205

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

3D-QSAR: a current perspective

By Green S.M.   Marshall G.R.  

Trends in Pharmacological Sciences, Vol. 16, Iss. 9, 1995-09 ,pp. : 285-291

Elsevier

Access to resources Recommend Favorite

Population Pharmacokinetics: A Regulatory Perspective

By Williams R.  

Clinical Pharmacokinetics, Vol. 37, Iss. 1, 1999-07 ,pp. : 41-58

Adis International

Access to resources Recommend Favorite

Risk Management: A European Regulatory Perspective

By Moseley J.N.S.  

Drug Safety, Vol. 27, Iss. 8, 2004-01 ,pp. : 499-508

Adis International

Access to resources Recommend Favorite

Tablet Scoring and its Regulatory Perspective

By  

Applied Clinical Research, Clinical Trials and Regulatory Affairs, Vol. 1, Iss. 2, 2014-01 ,pp. : 107-110

Bentham Science Publishers

Access to resources Recommend Favorite

Fixed-Dose Combination Therapy with Statins: Strengths, Limitations, and Clinical and Regulatory Considerations

By Hennekens Charles H.  

American Journal of Cardiovascular Drugs, Vol. 8, Iss. 3, 2008-01 ,pp. : 155-160

Adis International

Access to resources Recommend Favorite